SII to manufacture French firm's vaccine for chikungunya

THE DEVELOPMENT HOLDS PROMISE AS CHIKUNGUNYA IS ENDEMIC ACROSS THE COUNTRY, WITH 12,587 CASES RECORDED THIS YEAR SO FAR

- Rhythma Kaul

NEW DELHI: Serum Institute of India will manufacture the chikungunya vaccine for the Indian market and a few other Asian countries under a licensing agreement between the Pune-based company and France-based Valneva SE, a joint statement from the two companies said on Thursday.

The collaboration to support broader access to the vaccine in low-and-middle-income countries (LMICs) in the region falls within the framework of the $41.3 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2024 with co-funding from the European Union, the statement said.